13311-84-7MKXKFYHWDHIYRV-UHFFFAOYSA-NMKXKFYHWDHIYRV-UHFFFAOYSA-N
FlutamidePropanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-
4-Nitro-3-(trifluoromethyl)isobutyranilide
4'-Nitro-3'-trifluoromethylisobutyranilide
Eulexin
Flucinom
Flutamid
flutamida
m-Propionotoluidide, α,α,α-trifluoro-2-methyl-4'-nitro-
N-(Isopropylcarbonyl)-4-nitro-3-trifluoromethylaniline
Niftholide
Niftolide
NSC 147834
NSC 215876
DTXSID7032004PR:000004191androgen receptorCHEBI:17347testosteroneCL:0000178Leydig cellCHEBI:81568Luteinizing hormoneGO:0004882androgen receptor activityGO:0005102receptor bindingMP:0001152Leydig cell hyperplasiaMP:0002006neoplasm2decreased1increasedVinclozalin2016-11-29T18:42:272016-11-29T18:42:27Flutamide2016-11-29T18:42:272016-11-29T18:42:2710116Rattus norvegicusDecreased, Androgen receptor activityDecreased, Androgen receptor activityMolecular2016-11-29T18:41:262016-12-03T16:37:51Decreased, Testosterone binding to androgen receptor (hypothalamus)Decreased, Testosterone binding to androgen receptor (hypothalamus)MolecularCL:2000030hypothalamus native cell2016-11-29T18:41:262017-09-16T10:16:08Increase, Hyperplasia (Leydig cells)Increase, Hyperplasia (Leydig cells)CellularCL:0000178Leydig cell2016-11-29T18:41:262017-09-16T10:16:09Increase, Leydig cell tumorsIncrease, Leydig cell tumorsCellularCL:0000178Leydig cell2016-11-29T18:41:262017-09-16T10:16:09Increased, Luteinizing hormone (LH) Increased, Luteinizing hormone (LH) TissueUBERON:0000178blood2016-11-29T18:41:262017-09-16T10:16:097f5953ba-99ba-4c32-b93e-4faaf1d762070e00705f-be51-44d4-af8b-5e35bd4509d02016-11-29T18:41:352016-12-03T16:37:59097c103f-68a8-4fb3-a8c9-9137c89686cd4b8a9e1f-9ec1-4c17-a06d-84d546b188f32016-11-29T18:41:352016-12-03T16:37:590e00705f-be51-44d4-af8b-5e35bd4509d029812b4e-6c5b-41fd-8ae6-a4cd492a4de72016-11-29T18:41:352016-12-03T16:38:0029812b4e-6c5b-41fd-8ae6-a4cd492a4de7097c103f-68a8-4fb3-a8c9-9137c89686cd2016-11-29T18:41:352016-12-03T16:38:00Decrease in androgen receptor activity leading to Leydig cell tumors (in rat)Decreased AR activity- Leydig cell tumors<p>Cancer AOP group. National Health and Environmental Effects Research Laboratory, Office of Research and Development, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC. Corresponding author for wiki entry (wood.charles@epa.gov)</p>
Under Development: Contributions and Comments WelcomeUnder Development1.29<p>This putative adverse outcome pathway (AOP) outlines potential key events leading to a tumor outcome in standard carcinogenicity models. This information is based largely on modes of action described previously in cited literature sources and is intended as a resource template for AOP development and data organization. Presentation in this Wiki does not indicate EPA acceptance of a particular pathway for a given reference agent, only that the information has been proposed in some manner. In addition, this putative AOP relates to the model species indicated and does not directly address issues of human relevance.</p>
adjacentNot SpecifiedNot SpecifiedadjacentNot SpecifiedNot SpecifiedadjacentNot SpecifiedNot SpecifiedadjacentNot SpecifiedNot SpecifiedNot SpecifiedMaleNot Specified<p>Cook, J. C., Klinefelter, G. R., Hardisty, J. F., Sharpe, R. M., & Foster, P. M. (1999). Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit Rev Toxicol, 29(2), 169-261. doi: 10.1080/10408449991349203</p>
2016-11-29T18:41:162023-04-29T13:02:12